Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector128310.17816/ACEN.1283HUVVSTOriginal articlesОригинальные статьиResearch ArticleElectrophysiological markers of chemotherapy-induced polyneuropathyЭлектрофизиологические маркеры химиоиндуцированной полинейропатииhttps://orcid.org/0000-0002-1796-0193TikhonovaOlga A.ТихоноваОльга Алексеевна
Russian Federation

neurologist, assistant, Department of psychiatry and neurosciences

врач-невролог, ассистент каф. психиатрии и нейронаук

offelia78@mail.ruhttps://orcid.org/0000-0002-1004-992XDruzhininaEvgeniia S.ДружининаЕвгения Сергеевна
Russian Federation

Cand. Sci. (Med.), Associate Professor, Department of neurology, neurosurgery and medical genetics named after academician L.O. Badalyan, Faculty of pediatrics

кандидат медицинских наук, доцент каф. неврологии, нейрохирургии и медицинской генетики им. акад. Л.О. Бадаляна педиатрического факультета

offelia78@mail.ruhttps://orcid.org/0000-0002-6244-0867DruzhininDmitry S.ДружининДмитрий Сергеевич
Russian Federation

Dr. Sci. (Med.), Associate Professor, Department of nervous diseases with medical genetics and neurosurgery

доктор медицинских наук, доцент каф. нервных болезней с медицинской генетикой и нейрохирургией

offelia78@mail.ruImmanuel Kant Baltic Federal UniversityБалтийский федеральный университет имени Иммануила КантаPirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет имени Н.И. Пирогова (Пироговский Университет)Yaroslavl State Medical UniversityЯрославский государственный медицинский университет2606202519234403101202507042025Copyright ©; 2025, Tikhonova O.A., Druzhinina E.S., Druzhinin D.S.Copyright ©; 2025, Тихонова О.А., Дружинина Е.С., Дружинин Д.С.2025Tikhonova O.A., Druzhinina E.S., Druzhinin D.S.Тихонова О.А., Дружинина Е.С., Дружинин Д.С.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/1283

Introduction. Electrophysiological testing is the gold standard for diagnosing polyneuropathy. However, its use in oncology practice for patients with chemotherapy-induced polyneuropathy (CIPN) remains limited and the value of its findings is not fully understood.

The study was aimed at identifying electrophysiological CIPN markers and evaluting their sensitivity and specificity.

Materials and methods. The study included patients (n = 71) over 18 years of age with solid tumor presenting with polyneuritic complaints following neurotoxic therapy with platinum-based agents and taxanes. Patients with known risk factors for polyneuropathy were excluded. Electrophysiological and clinical patient data were evaluated no earlier than 3 months following chemotherapy initiation.

Results. The study identified electromyographic markers: SRAR index (sural/radial ratio — the ratio between the action potential amplitudes of the sural and radial nerves) and the sural nerve action potential (SNAP), demonstrating equal sensitivity (73.7%) and high specificity (75% and 84.6%, respectively).

Conclusion. Electromyographic parameters such as SRAR and SNAP sural nerve can be utilized for the diagnosis and monitoring of CIPN in daily practice.

Введение. Электрофизиологическое исследование является стандартом при диагностике полинейропатии. Пока его использование ограничено в онкологической практике у пациентов с химиоиндуцированной полинейропатией (ХИПН), а ценность полученных результатов не до конца понятна.

Цель исследования — выявить электрофизиологические маркеры ХИПН и оценить их чувствительность и специфичность.

Материалы и методы. В исследование были включены пациенты (n = 71) старше 18 лет с солидными злокачественными новообразованиями, предъявляющие полиневритические жалобы после нейротоксической терапии с использованием препаратов платины и таксанов. Исключались пациенты с известными факторами риска развития полинейропатии. Изучали электрофизиологические, клинические данные пациентов не ранее чем через 3 мес после старта химиотерапии.

Результаты. В ходе исследования выявлены электромиографические маркеры: индекс SRAR (sural/radial ratio — соотношение между амплитудой потенциала действия икроножного и лучевого нервов) и потенциал действия икроножного нерва с равной чувствительностью (73,7%) и высокой специфичностью (75 и 84,6% соответственно).

Заключение. Для диагностики и мониторинга ХИПН в ежедневной практике могут использоваться электромиографические показатели, такие как SRAR и потенциал действия икроножного нерва.

electroneuromyographychemotherapy-induced polyneuropathymarkersSRARcancerэлектронейромиографияхимиоиндуцированная полинейропатиямаркерыSRARрак«Приоритет 2030» программа стратегического академического лидерстваSeretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. doi: 10.1016/j.pain.2014.09.020Fuglsang-Frederiksen A, Pugdahl K. Current status on electrodiagnostic standards and guidelines in neuromuscular disorders. Clin Neurophysiol. 2011;122(3):440–455. doi: 10.1016/j.clinph.2010.06.025Novello BJ, Pobre T. Electrodiagnostic evaluation of peripheral neuropathy. Treasure Island; 2025.Griffith KA, Dorsey SG, Renn CL, et al. Correspondence between neurophysiological and clinical measurements of chemotherapy‐induced peripheral neuropathy: secondary analysis of data from the CI‐PERINOMS study. J Peripher Nerv Syst. 2014;19(2):127–135. doi: 10.1111/jns5.12064Cho KH, Han EY, Shin JC, et al. Comparison of clinical symptoms and neurophysiological findings in patients with chemotherapy induced peripheral neuropathy. Front Neurol. 2022;13:838302. doi: 10.3389/fneur.2022.838302Wang M, Bandla A, Sundar R, Molassiotis A. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: a secondary analysis of pooled data. Eur J Oncol Nurs. 2022; 60:102196. doi: 10.1016/j.ejon.2022.102196Супонева Н.А., Арестова А.С., Мельник Е.А. и др. Валидация шкалы суммарной оценки мышечной силы (MRC sum score) для использования у русскоязычных пациентов с хронической воспалительной демиелинизирующей полинейропатией. Нервно-мышечные болезни. 2023;13(1):68–74. Suponeva NA, Arestova AS, Melnik EA, et al. Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy. Neuromuscular Diseases. 2023;13(1):68–74. doi: 10.17650/2222-8721-2023-13-1-68-74Mooi CS, Lee KW, Yusof Khan AHK, et al. Using biothesiometer, Neuropathy Symptom Score, and Neuropathy Disability Score for the early detection of peripheral neuropathy: a cross-sectional study. Qatar Med J. 2024;2024(3):24. doi: 10.5339/qmj.2024.24Using the Common Terminology Criteria for Adverse Events (CTCAE — Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–92. doi: 10.1016/j.ad.2019.05.009Stålberg E, Van Dijk H, Falck B, et al. Standards for quantification of EMG and neurography. Clin Neurophysiol. 2019;130(9):1688–1729. doi: 10.1016/j.clinph.2019.05.008Electromyography and neuromuscular disorders: clinical-electrodiagnostic-ultrasound correlations, Fourth Edition. J Clin Neurophysiol. 2021;38(4):e19. doi: 10.1097/WNP.0000000000000842Esper GJ, Nardin RA, Benatar M, et al. Sural and radial sensory responses in healthy adults: diagnostic implications for polyneuropathy. Muscle Nerve. 2005;31(5):628–632. doi: 10.1002/mus.20313Overbeek BUH, Van Alfen N, Bor JA, Zwarts MJ. Sural/radial nerve amplitude ratio: reference values in healthy subjects. Muscle Nerve. 2005;32(5):613–618. doi: 10.1002/mus.20421Rutkove SB, Kothari MJ, Raynor EM, et al. Sural/radial amplitude ratio in the diagnosis of mild axonal polyneuropathy. Muscle Nerve. 1997;20(10):1236–1241. doi: 10.1002/(sici)1097-4598(199710)20:10<1236::aid-mus5>3.0.co;2-dVan Den Bergh PYK, Van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force — Second revision. J Peripher Nerv Sys. 2021;26(3):242–268. doi: 10.1111/jns.12455Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, et al. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018;18(1):958. doi: 10.1186/s12885-018-4869-5Jordan B, Jahn F, Sauer S, Jordan K. Prevention and management of chemotherapy-induced polyneuropathy. Breast Care (Basel). 2019;14(2):79–84. doi: 10.1159/000499599Timmins HC, Mizrahi D, Li T, et al. Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. 2023;17(1):222–236. doi: 10.1007/s11764-021-00988-xMorton RF, Sloan JA, Grothey A, et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. JCO. 2005;23(16):8087. doi: 10.1200/jco.2005.23.16_suppl.8087Park SB, Kwok JB, Asher R, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28(11):2733–2740. doi: 10.1093/annonc/mdx491Burakgazi AZ, Messersmith W, Vaidya D, et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980–986. doi: 10.1212/WNL.0b013e31822cfc59Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132. doi: 10.1186/s12885-019-5302-4Холодова Н.Б., Понкратова Ю.А., Синкин М.В. Клинические и электронейромиографические особенности постхимиотерапевтической полинейропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(9):59–66. Kholodova NB, Ponkratova YuA, Sinkin MV. Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):59–66. doi: 10.17116/jnevro20171179159-66Kim SH, Kim W, Kim JH, et al. A Prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy. J Clin Neurol. 2018;14(1):81–89. doi: 10.3988/jcn.2018.14.1.81Myftiu B, Hundozi Z, Sermaxhaj F, et al. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in patients receiving 4–6 cycles of platinum-based and taxane-based chemotherapy: a prospective, single-center study from Kosovo. Med Sci Monit. 2022;28: e937856. doi: 10.12659/MSM.937856.Mansukhani K, Dhonde M, Sreenivasan A, et al. Sural radial amplitude ratio: a study in healthy Indian subjects. Ann Indian Acad Neurol. 2020;23(3):255–260. doi: 10.4103/aian.AIAN_321_20Guo Y, Palmer JL, Brown XS, Fu JB. Sural and radial sensory responses in patients with sensory polyneuropathy. Clin Med Rev Case Rep. 2015;2(3):049. doi: 10.23937/2378-3656/1410049